Trial Profile

IMPACT: Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 15 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
Indications Adenocarcinoma; Carcinoma; Prostate cancer; Solid tumours
Focus Therapeutic Use
Acronyms IMPACT

Most Recent Events

28 Aug 2024 Status changed from active, no longer recruiting to completed.
21 Jun 2023 Planned End Date changed from 1 May 2023 to 1 Dec 2024.
01 Aug 2022 Treatment arms increased from 2 to 3

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com